SCHEDULE: Gabelli Funds Opposes DallasNews Poison Pill, Weighs Hearst Bid

Gabelli Funds and affiliated entities have increased their stake in DallasNews Corp to 6.08% and expressed opposition to the company's recently adopted 10% poison pill, while evaluating a proposed acquisition by Hearst Communications Inc.

Summary

• Reporting Persons, including Gabelli Funds, GAMCO Asset Management Inc., and GABELLI & Co Investment Advisers, Inc., collectively beneficially own 287,926 shares of DallasNews Corp Series A Common Stock, representing 6.08% of the 4,739,025 shares outstanding as of August 14, 2025.
• An aggregate of approximately $540,368 was used by the Reporting Persons to purchase additional securities since the most recent Schedule 13D filing, primarily through client funds.
• DallasNews Corp's Board of Directors adopted a 10% poison pill on July 27, 2025, without shareholder approval, which the Reporting Persons view as inconsistent with their proxy voting guidelines.
• The Reporting Persons are currently evaluating the proposed acquisition of DallasNews Corp by Hearst Communications Inc. and have not yet determined how they will vote at the special meeting on September 23, 2025.
• GAMCO's long-standing policy, outlined in its May 1988 Magna Carta of Shareholder Rights, generally opposes poison pills.
• The decision on the acquisition will consider various factors, including the recently adopted poison pill.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the company's adoption of a poison pill without shareholder approval, which is explicitly opposed by the Reporting Persons. While the increased stake shows continued interest, the governance issue introduces a significant point of contention and potential risk.

Positives

• Reporting Persons increased their aggregate beneficial ownership to 6.08%, indicating continued investment interest in DallasNews Corp.

Negatives

• DallasNews Corp's Board adopted a 10% poison pill without shareholder approval, which is viewed negatively by the Reporting Persons and is inconsistent with their proxy voting guidelines.

Risks

• The adoption of a poison pill without shareholder approval could signal potential governance issues or management's intent to deter hostile takeovers, potentially limiting shareholder value.
• Uncertainty regarding the outcome of the special meeting on September 23, 2025, for the proposed acquisition by Hearst Communications Inc., could create market volatility.
• The poison pill may complicate or deter future acquisition offers, potentially impacting the company's strategic options and shareholder returns.

Future Outlook

Reporting Persons are evaluating the evolving dynamics of the proposed acquisition by Hearst Communications Inc. and the implications of the recently adopted poison pill before making a determination on their vote at the upcoming special meeting. Their decision will be influenced by the inconsistency of the poison pill with their proxy voting guidelines.

Management Comments

• "The recently adopted poison pill is inconsistent with our proxy voting guidelines and may enter into our decision making process as one of the many factors we will be examining."
• "The Reporting Persons have not yet reached a conclusion on how they intend to vote at the Issuer's September 23rd special meeting, which seeks approval for the proposed acquisition of the company by Hearst Communications Inc."
• "GAMCO continues to evaluate the evolving dynamics before making a determination."

Industry Context

This filing highlights an activist investor's stance on corporate governance issues, specifically the adoption of a poison pill, within the media industry. Such actions often reflect broader concerns among institutional investors regarding shareholder rights and management's control in the face of potential M&A activities. The involvement of a major media conglomerate like Hearst Communications Inc. in a potential acquisition underscores ongoing consolidation and strategic realignments within the sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The poison pill could dilute shareholder voting power and deter potential acquirers, potentially limiting upside from M&A. The Reporting Persons' opposition signals a potential conflict between management and a significant shareholder group.
• Management: The poison pill may strengthen management's position against unsolicited takeover bids, but could also lead to increased scrutiny and potential conflict with activist investors.

Next Steps

• Reporting Persons will determine their vote on the proposed acquisition by Hearst Communications Inc. at the special meeting on September 23, 2025.

Key Dates

Recommendation

The filing indicates a significant corporate governance issue with the adoption of a poison pill without shareholder approval, which is explicitly opposed by a major institutional investor group. This creates uncertainty and potential conflict. However, the Reporting Persons are still evaluating a proposed acquisition, which could be a positive catalyst if approved. Given the conflicting signals – a negative governance move versus a potential M&A event – a 'hold' recommendation is appropriate until the outcome of the special meeting and the investor group's final stance are clear. Investors should monitor developments closely, particularly the vote on the Hearst acquisition and any further statements from the Reporting Persons.

Keywords

DallasNews Corp, Gabelli Funds, GAMCO, Poison Pill, Shareholder Rights, Hearst Communications, Acquisition, Corporate Governance, Schedule 13D, Beneficial Ownership